3/23/2011

Amgen agreed to exclusively license its anaplastic lymphoma kinase technology to Tesaro to help develop drugs for nonsmall-cell lung cancer. The deal calls for Tesaro to pay upfront and milestone fees to Amgen in exchange for development, production and marketing rights to ALK small-molecule drugs.

Related Summaries